Professional
Added to YB: 2025-01-09
Pitch date: 2025-01-07
BVNRY [bullish]
Bavarian Nordic A/S
+7.49%
current return
Author Info
No bio for this author
Company Info
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
Market Cap
$15.2B
Pitch Price
$9.08
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.47
P/E
13.67
EV/Sales
2.21
Sector
Biotechnology
Category
growth
Protean Funds Scandinavia AB New Position: Bavarian Nordic A/S
BVNRY: Danish vaccine co. Strong travel vaccine franchise (rabies, TBE) growing. TBE benefits from climate change. Travel vaccines attractive for growth/M&A. Low generic risk. Jynneos (smallpox/monkeypox) adds optionality. Consolidating production to improve margins in 2025. Initiating mid-sized position.
Read full article (1 min)